Business Wire

Other World Computing to Debut New Thunderbolt 5 Dual 10GbE Network Dock Alongside Its Industry-Leading Roster of Storage and Connectivity Solutions at IBC2025

9.9.2025 14:30:00 CEST | Business Wire | Press Release

Share

Other World Computing (OWC®), a trusted leader in high-performance storage, memory, connectivity, software, and accessories that empower creative and business professionals to maximize performance, enhance reliability, and streamline workflows, today announced it will debut its new OWC Thunderbolt 5 Dual 10GbE Network Dock, as well as showcase its unrivaled roster of storage and connectivity solutions, at IBC2025, taking place September 12-15 (RAI Amsterdam).

Visitors to OWC’s Booth – Hall 7, Booth 7.A60 – will have the opportunity to see first-hand a wide range of OWC storage and connectivity innovations relied on by top creative and business professionals worldwide.

New Product Debuts:

- OWC Thunderbolt 5 Dual 10GbE Network Dock - This powerful dock enables users to connect to multiple high-speed networks, access blazing-fast network-attached storage (NAS), and expand device setups via a single Thunderbolt cable.

- ​​OWC Express 1M2 80G - An evolutionary leap forward in portable SSD performance for creators in the field, mobile performance enthusiasts, and gamers. With over 6,000MB/s real-world peak speeds, it is ThunderboltTM 5 compatible and delivered in a palm-sized, fanless form factor.

- OWC Express 4M2 - A four-slot NVMe M.2 SSD USB4, SoftRAID-enabled enclosure offering 3,200MB/s of improved performance, thermal protection for today’s high-performance drives, and expanded compatibility for an improved near-silent operation.

Other Notable Products:

- OWC Jellyfish S24 - Offers a full SSD production server with lightning-fast performance for demanding video workflows. With scalable expansion options and rock-solid reliability, OWC Jellyfish solutions give video editors, post-production teams, and content creators the tools they need to work faster, collaborate more easily, and keep their projects moving - without storage ever slowing them down.

- OWC Thunderbolt 5 Dock - Built to meet the demands of creatives, power users, and professionals alike, this all-in-one connectivity solution redefines desktop performance. With exceptional speed, broad device compatibility, and outstanding visual output, the OWC Thunderbolt 5 Dock sets a new benchmark for workstation expansion and productivity.

- OWC ThunderBlade X12 - The answer to Motion Picture Professionals and DITs looking for a production shuttle RAID capable of offering large amounts of storage (up to 96TB) at blazingly fast sustained speeds in a portable solution. It’s also a premium editing drive for video editors and VFX artists working with cutting-edge workflows such as multi-cam sequences at 4K and 6K, 8K and 12K RAW video, or stereoscopic 360 VR (Spatial Video).

“We are excited to attend IBC2025 and for the opportunity it affords us to meet with the professionals that are shaping the future of this industry,” said Larry O’Connor, CEO and Founder, Other World Computing. “Being able to learn first-hand about the real-world goals and challenges they face every day is indeed invaluable. As is the chance to share how OWC solutions can enable them to collaborate more easily, move faster, and bring stories to life in ways that entertain, educate, and inspire audiences everywhere.”

IBC2025 is an event that connects pioneers and thought leaders from around the world who are redefining how content is created, distributed, and consumed. To learn more and register to attend IBC2025, please visit: https://show.ibc.org/.

About Other World Computing (OWC)

Founded in 1988, Other World Computing (OWC®) is a trusted leader in high-performance storage, docks, and memory card solutions that empower professionals in video and audio production, photography, and business with the tools to maximize the performance and reliability of their workflows seamlessly. OWC’s professional-grade storage, expansion, media cards, docks, and connectivity, as well as its apps and accessories, are built to last by the people who use them: creatives, businesses, and consumers. For further information, please visit www.owc.com. OWC can also be found on LinkedIn and X.

©2025 Other World Computing (OWC). All other brand and product names contained in this announcement may be trademarks or registered trademarks of their respective holders.

Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909302684/en/

Contacts

PR Contact:
Nicole Gorman
Gorman Communications, for Other World Computing (OWC)
M: 508-397-0131
nicole.gorman@gormancommunications.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye